Therapeutics News and Research

RSS

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Preliminary data from Amorfix human diagnostic test for Alzheimer's presented at ICAD

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, presented a paper on Sunday July 17th, 2011 at the International Conference on Alzheimer's disease in Paris, France.

19 Jul 2011

Cell Biosciences is now ProteinSimple

Cell Biosciences, Inc. today announced that it has changed its name to ProteinSimple to clearly reflect the Company's core mission in protein research.

From ProteinSimple 18 Jul 2011

QRxPharma seeks NDA approval for MoxDuo IR

QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.

18 Jul 2011

FDA asks Guided Therapeutics to provide additional information on LuViva PMA

Guided Therapeutics, Inc., developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that, after a series of meetings with the U.S. Food and Drug Administration (FDA), and after reviewing draft responses, the FDA has asked the company to provide additional information in the company's response to one remaining question.

15 Jul 2011

Yervoy, a new melanoma drug approved in Australia

Australia has approved the world’s first drug to prolong the lives of people with advanced melanoma. The drug Yervoy received the nod from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the deadliest form of skin cancer but for whom other treatments have failed.

14 Jul 2011

IMM researcher wins prestigious Early Career Bayer Hemophilia Award

Vanessa Oliveira, researcher at the Instituto de Medicina Molecular in Portugal won a prestigious and competitive Early Career Bayer Hemophilia Award. Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics.

14 Jul 2011

Accelrys releases Discovery Studio software for biotherapeutics research

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced a new release of the Discovery Studio life sciences modeling and simulation software.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

UIC to begin STX209 clinical trial for treatment of autism spectrum disorders

An experimental drug to treat social withdrawal in children and young adults with autism is being studied in a clinical trial at the University of Illinois at Chicago's Institute for Juvenile Research.

13 Jul 2011

Two papers highlight therapeutic potential of human Sertoli cells

Two papers published in the current issue of Cell Transplantation, now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, highlight the therapeutic potential of human Sertoli cells that are present in the testes and are also called "nurse" or "mother" cells because they nurture the developing sperm cells.

12 Jul 2011

Cancer Cell publishes Epizyme and collaborators' breakthrough research on MLL

Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.

12 Jul 2011

iBio successfully produces human plasma proteins using proprietary technology

iBio, Inc. today announced successful production of human plasma proteins using its proprietary iBioLaunch technology. Human alpha 1-antitrypsin and human C1 esterase inhibitor were successfully produced at high yield in green plants via the Company's proprietary iBioLaunch technology. Both of these proteins are important therapeutic products, but until now they have been made from human blood.

11 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Isogenica opens new automation facility

Isogenica Ltd today announced the opening of a new automation facility at their current location, Chesterford Research Park.

11 Jul 2011

Scientists convert brain cells into cardiomyocytes

For the past decade, researchers have tried to reprogram the identity of all kinds of cell types. Heart cells are one of the most sought-after cells in regenerative medicine because researchers anticipate that they may help to repair injured hearts by replacing lost tissue.

11 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Extensive genomic, transcriptional diversity identified through massively parallel DNA and RNA sequencing

In a paper published in the online edition of Nature Genetics on July 3, 2011, sequencing specialists at Axeq Technologies, and scientists from Macrogen Inc., Genomic Medicine Institute at Seoul National University, Psoma Therapeutics Inc., Brigham and Women's Hospital and Harvard Medical School reported the discovery of a wide range of novel genetic variants based on the deep sequencing of 18 genomes and 17 transcriptomes of unrelated Korean individuals.

8 Jul 2011

New technique may help scientists probe mysteries of many different stem cells

Researchers at the Salk Institute have been able to genetically incorporate "unnatural" amino acids, such as those emitting green fluorescence, into neural stem cells, which then differentiate into brain neurons with the incandescent "tag" intact.

8 Jul 2011